Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jun;17(6):50.
doi: 10.1007/s11910-017-0754-x.

The Potential of Cellular- and Viral-Based Immunotherapies for Malignant Glioma-Dendritic Cell Vaccines, Adoptive Cell Transfer, and Oncolytic Viruses

Russell Maxwell  1 , Andrew S Luksik  1 , Tomas Garzon-Muvdi  1 , Michael Lim  2
Affiliations
Review

The Potential of Cellular- and Viral-Based Immunotherapies for Malignant Glioma-Dendritic Cell Vaccines, Adoptive Cell Transfer, and Oncolytic Viruses

Russell Maxwell et al. Curr Neurol Neurosci Rep. 2017 Jun.

Abstract

Purpose of review: Malignant gliomas, including glioblastoma and anaplastic astrocytoma, are the most frequent primary brain tumors and present with many treatment challenges. In this review, we discuss the potential of cellular- and viral-based immunotherapies in the treatment of malignant glioma, specifically focusing on dendritic cell vaccines, adoptive cell therapy, and oncolytic viruses.

Recent findings: Diverse cellular- and viral-based strategies have been engineered and optimized to generate either a specific or broad antitumor immune response in malignant glioma. Due to their successes in the preclinical arena, many of these therapies have undergone phase I and II clinical testing. These early clinical trials have demonstrated the feasibility, safety, and efficacy of these immunotherapies. Dendritic cell vaccines, adoptive cell transfer, and oncolytic viruses may have a potential role in the treatment of malignant glioma. However, these modalities must be investigated in well-designed phase III trials to prove their efficacy.

Keywords: Adoptive cell transfer; CAR T cells; Dendritic cell vaccines; Glioma; Immunotherapy; Oncolytic virus.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Neurosurg Focus. 2000 Dec 15;9(6):e9 - PubMed
    1. Oncoimmunology. 2015 Dec 21;5(4):e1119354 - PubMed
    1. Cancer Immunol Res. 2014 Apr;2(4):295-300 - PubMed
    1. Arch Surg. 1990 Feb;125(2):200-5 - PubMed
    1. J Natl Cancer Inst. 2007 Dec 5;99(23):1768-81 - PubMed

Substances

LinkOut - more resources